Fund moves

Iovance Biotherapeutics (IOVA): Avoro Capital Advisors LLC reduced its stake -740K shares

Avoro Capital Advisors LLC reduced its stake in Iovance Biotherapeutics, per its Q4 2024 13F.

3.5M
Shares reported · -740K vs prior quarter
0.37%
Disclosed portfolio weight
$25.9M
Reported value
Holdings as of
Dec 31, 2024
Filed
Feb 14, 2025

What stands out in this filing

  • 4,240,000 shares in Q3 2024, 3,500,000 now (−17.5% in share count).
  • Reported at $25.9M, 0.37% of the portfolio value in this 13F filing.
  • 3 other tracked managers reported the same kind of change for Q4 2024.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

    What came next

    1. May 14, 2025InsiderCEO purchased ~$42K of IOVA shares in the open market
    2. May 23, 2025InsiderOfficer purchased ~$9.7K of IOVA shares in the open market
    3. Jun 5, 2025InsiderOfficer purchased ~$55K of IOVA shares in the open market
    View the official recordSEC Form 13F-HR

    How to read SEC Form 13F-HR

    Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

    Full guide: What is an SEC Form 13F?

    What else is on file for Iovance Biotherapeutics

    For Iovance Biotherapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

    These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IOVA page.

    How this filing works

    Explore the data

    Common questions

    What does this filing report about Iovance Biotherapeutics (IOVA) stock?

    Avoro Capital Advisors LLC reduced its stake in Iovance Biotherapeutics, per its Q4 2024 13F. Now 3.5M shares, $25.9M reported value, 0.37% of disclosed portfolio.

    When did it happen, and when was it made public?

    Holdings as of: Dec 31, 2024. Filed: Feb 14, 2025.

    What stands out in this filing?

    4,240,000 shares in Q3 2024, 3,500,000 now (−17.5% in share count). Reported at $25.9M, 0.37% of the portfolio value in this 13F filing. 3 other tracked managers reported the same kind of change for Q4 2024.

    Is this a trade made on a known date?

    No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

    Where does this information come from?

    From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

    What else has been disclosed about Iovance Biotherapeutics recently?

    For Iovance Biotherapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the IOVA page.

    Does this mean IOVA stock is a buy or a sell?

    No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

    Is OQRO free?

    Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

    Other disclosures at Iovance Biotherapeutics

    Everything OQRO holds on this company is on its IOVA page.

    This is one filing. OQRO holds the rest

    Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

    OQRO is free for everyone. No card, no trial

    OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data